Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables

Merck announced the initiation of its Phase III program for oral PCSK9 inhibitor MK-0616 • Source: Shutterstock

More from Clinical Trials

More from R&D